611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net
Medical Disorders
Resources
Basic InformationLookupsLatest News
AHA News: Women May Be More Willing Than Men to Donate OrgansDNA Sensor Can Spot When COVID Is ContagiousTrials Show COVID Vaccines Well Worth It for Cancer PatientsCDC Endorses Booster Shots for Millions of AmericansChildhood Trauma Linked With Higher Odds for Adult Neurological IllsStudy Probes Relationship Between Migraines and SleepCancer in Hispanics: Good News and BadFDA Approves Pfizer Booster Shots for Seniors, High-Risk AmericansU.S. to Buy 500 Million More COVID Vaccine Doses for Global DonationAntibodies to Early Strains of COVID May Not Fight New Variants: StudyPregnant Women Who Get COVID Vaccine Pass Antibodies to NewbornsCDC Expert Panel to Weigh In on Vaccine BoostersWhich Kids Are at Highest Risk From COVID?4 Out of 10 Adults With No Known Heart Disease Have Fatty Hearts: StudyBooster Dose of J&J COVID Vaccine Increases ImmunityPost-Stroke Rehab: There's a Sweet Spot in the TimingCommon Form of Liver Cancer on the Rise in Rural AmericaCOVID Has Killed More Americans Than the Spanish Flu Did in 1918Telemedicine Gets High Marks for Follow-Ups After SurgeryPandemic Tied to Declining Birth Rates for U.S., Much of EuropeStudy Spots People at High Risk of Severe Breakthrough COVIDReview of Booster Shots for Moderna, J&J Vaccines Just Weeks Away: FauciDelta Variant Now Fueling 99% of U.S. COVID CasesLower Dose of Pfizer COVID Vaccine Works Well in Young Children, Company SaysFDA Panel OKs Pfizer Booster Shot for  People 65 or Older, But Not YoungerLong-Haul COVID in Kids Typically Ends Within 3 Months: StudyPfizer, Moderna Vaccines Still Offer Good Protection Against Severe COVID: StudyTrial Into Antioxidant for Parkinson's Disease Yields Disappointing ResultsIs Flu Ready for a Comeback? Get Your ShotCommon Eye Conditions Tied to Higher Risk for DementiaDrug Might Stop Heart Trouble Linked to Sickle Cell AnemiaChild Obesity Rose Sharply During PandemicFDA Advisory Panel to Meet on COVID Booster ShotsStatin Cholesterol Drugs May Help Fight Ulcerative ColitisAHA News: Physical Activity Is Helpful After a Stroke, But How Much Is Healthy?Special 'Strategies' Can Help People With Parkinson's Walk, But Many Patients UnawareEven When Undergoing Treatment, People With MS Gain From COVID VaccinesNIH Spending Nearly $470 Million on Long-Haul COVID StudyHospitalizing the Unvaccinated Has Cost U.S. Nearly $6 BillionIn 16 States, 35% or More Residents Now Obese: CDCPet Store Puppies Passing Drug-Resistant Bacteria to PeopleIs a Combo COVID/Flu Shot on the Way?1 in 500 Americans Has Died From COVID-19Having Even a Cousin or Grandparent With Colon Cancer Raises Your Risk: StudyBlood Cancer Patients Could Benefit From COVID Booster Shot: StudyWHO Says Africa Will Get 30% of COVID Vaccines It Needs by FebruaryCOVID Vaccines for Kids Under 12 Could Come This Fall: FauciEbola Vaccine Effective in African Clinical TrialBritain OK's COVID Vaccine for Kids 12 and Older; Hopes to Avoid LockdownsIsraeli Data on COVID Boosters to Be Published This Week in Major Journal
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Ebola Vaccine Effective in African Clinical Trial

HealthDay News
by Steven Reinberg
Updated: Sep 14th 2021

new article illustration

TUESDAY, Sept. 14, 2021 (HealthDay News) -- An experimental Ebola vaccine appeared effective in children and adults in a clinical trial.

Two doses of Johnson & Johnson's Ebola vaccine appear safe, well tolerated and produce a strong immune response in people over the age of 1, according to two just-published papers.

The trial was conducted in the West African nation of Sierra Leone.

"Working in tandem with Sierra Leone colleagues and the local communities, this is the first published study to evaluate this two-dose vaccine regime in a randomized controlled trial in children," said study leader Dr. Muhammed Afolabi, an assistant professor at the London School of Hygiene & Tropical Medicine (LSHTM).

"The results show that this vaccine regimen has the potential to save many young lives," he said in a school news release.

The EBOVAC-Salone study provides evidence for the potential of the two-dose regimen as a way to prevent Ebola in children and adults.

Researchers found that it was well tolerated and induced antibody responses 21 days after the second dose in 98% of participants. The immune responses persisted in adults for at least two years.

During a 2014-2016 Ebola outbreak, West Africa had nearly 29,000 cases and more than 11,000 deaths. About 20% of cases were in children under age 15, and those under 5 had a higher risk of dying than adults, researchers noted. The disease causes fever, aches, pains and unexplained hemorrhaging, bleeding or bruising.

"This study represents important progress in the development of an Ebola virus disease vaccine regimen for children, and contributes to the public health preparedness and response for Ebola outbreaks," Afolabi said.

For the study, 43 adults received the Ad26.ZEBOV vaccine followed by the MVA-BN-Filo vaccine after 56 days. In the next stage, 400 adults and 576 children and teens were vaccinated with either that regimen or a single dose of a meningococcal vaccine followed by placebo on day 57.

Adults participating in the first stage of the study were offered a booster dose of Ad26.ZEBOV two years after the first dose. Researchers reported it induced a strong immune response within a week.

"To protect people from Ebola, we will need a range of effective interventions," said co-author Dr. Daniela Manno of LSHTM. "These findings support the additional strategy of providing an Ad26.ZEBOV booster to previously immunized individuals at the start of an Ebola virus disease outbreak."

The findings contributed to the approval and marketing of the two-dose Ebola vaccine regimen in July 2020 by the European Medicines Agency, for both children and adults. It also contributed to prequalification in April 2021 by the World Health Organization (WHO).

"The threat of future Ebola virus disease outbreaks is real and it's important to remember that this disease has definitely not gone away," said co-author Deborah Watson-Jones, a professor at LSHTM. "Despite the additional global challenges around COVID-19, we must not slow down efforts to find effective ways of preventing Ebola virus epidemics and, should outbreaks occur, of containing them rapidly."

Vaccines have a key role in meeting both objectives, she added.

In May, Johnson & Johnson said it would donate thousands of Ebola vaccine regimens in support of a WHO early access program. The program was launched in response to an outbreak in Guinea and aimed at preventing Ebola in West Africa.

The findings were published Sept. 13 in the journal The Lancet Infectious Diseases.

More information

To learn more about Ebola, visit the U.S. Centers for Disease Control and Prevention.

SOURCE: London School of Hygiene & Tropical Medicine, news release, Sept. 13, 2021